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Introduction
Improved glycemic control in patients with diabetes mellitus reduces the incidence of long-term complications, particularly microvascular disease. [1] [2] [3] In patients with type 2 diabetes, the need for adequate metabolic control has led to the advocacy of more intensive treatment regimens, including basal-bolus insulin therapy. 4, 5 While several studies corroborate the rigorous basal-bolus regimen, 6-10 many patients still resist insulin therapy in general and intensive insulin regimens in particular. [11] [12] [13] [14] [15] [16] Fear of injection, hypoglycemia, and weight gain hinder patient compliance, in addition to the inconvenience and embarrassment caused by frequent injections. 14, 15, 17, 18 Insulin injection pens provide a convenient, accurate, preferred alternative to vial and syringe systems, with improved compliance. 16, [18] [19] [20] [21] [22] However, not all insulin pens consistently deliver accurate doses and instead may over-or underdose. 23, 24 Glycemic variations may result, ultimately providing suboptimal glycemic control.
With the rigors of the basal-bolus treatment regimen in mind, the Levemir ® (insulin detemir) FlexPen ® (Novo Nordisk A/S, Copenhagen, Denmark) was designed to help patients conveniently and accurately adhere to treatment, supporting patient confidence in self-management of diabetes. This noninvasive study investigated the ease of use of two insulin pens: the Levemir FlexPen and the OptiClik ® pen with Lantus ® (insulin glargine) (Sanofi-Aventis, Paris, France). In this study the following were investigated: (1) intuitive use (without instruction) of the insulin pens by injection time measurement and questionnaire, (2) instruction time needed to complete an injection, and (3) ease of use; perceptions of safety, reliability, and durability; trust and confidence in the device; and overall pen preference.
Patients and Methods

Patients
Patients with type 2 diabetes were included if they were on oral antidiabetes drug (OAD) treatment for at least 2 years, aged ≥18 years, and had no prior experience with insulin injection devices. Patients were excluded if they did not meet these requirements, were unable to read newspaper body text, or had neuropathy, visual impairment, and/or motor disabilities.
Study Design
This randomized open-label crossover noninvasive superiority investigation was conducted according to all applicable regulatory requirements, and written consent was received from all patients in accordance with the Declaration of Helsinki. The study compared the FlexPen with OptiClik in insulin-device-naive Japanese patients with type 2 diabetes. Overall the test took approximately 1 to 1.5 h.
Sixty-one patients were randomized into either the intuitiveness group or the instruction time group (Figure 1) . Patients were randomized again into either sequence: FlexPen followed by OptiClik or OptiClik followed by FlexPen. Figure 1 . Study flow chart. Sixty-one patients were enrolled and randomized into either the intuitiveness group (n = 32) or the instruction time group (n = 29). In each group, patients were randomized to a treatment sequence: either Levemir FlexPen followed by OptiClik with Lantus or OptiClik with Lantus followed by Levemir FlexPen. Finally the patients were asked to answer several questionnaires.
FlexPen is a prefilled insulin pen that does not require replacement of insulin cartridges, whereas OptiClik is a reusable insulin pen requiring insulin cartridge replacement.
The intuitiveness group did not receive instructions on how to use the insulin pens. Patients were timed on how long it took to intuitively inject the pen into a needle cushion, with and without cartridge insertion (for OptiClik only). Patients in the instruction time group received instructions on how to operate the insulin pens, including cartridge insertion (for OptiClik only).
Only patients in the intuitiveness group completed a questionnaire regarding intuitiveness and device understanding (IG questionnaire) after both pens had been tested. Patients in both groups then completed the important features of the devices (IFD) questionnaire. Afterward, all patients were given the insulin pens again and received thorough instructions on how to use each pen. Patients completed questionnaires on ease of use [learning to use questionnaire (LQ)] and overall preference [handling and acceptance questionnaire (HAQ)].
Efficacy Assessments
The primary endpoint in the intuitiveness group was the injection time in minutes and seconds taken to deliver a specific dose (10 U) into a needle cushion, with and without cartridge insertion. Additional intuitive endpoints included determining (1) which insulin pen was the most intuitive to use without instruction and (2) confidence level in using either insulin pen without instruction (IG questionnaire). The primary endpoint in the instruction time group was the injection time with instruction needed to successfully inject a specific dose (10 U) into a needle cushion, with or without cartridge insertion. Secondary endpoints for both groups included assessing ease of use; perceptions of safety, reliability, and durability; trustfulness; confidence; and overall preference, using questionnaires.
Statistical Analysis
Injection times were analyzed using an analysis of variance, including device, period (1 or 2), and group, as main fixed effects, and an interaction effect between the group and device. Differences were considered significant if p < .05. Patient preferences were assessed by questionnaires. For preference variables, the frequencies of preference or nonpreference were calculated together with the associated 95% confidence interval (CI) and p value of no difference. All other nonpreference variables from the questionnaires involving pairwise comparison were analyzed using a Pearson test for independence of the patient evaluation.
Results
Demographic and Other Baseline Characteristics
Sixty-one patients were randomized and completed the study ( Table 1) . Mean (SD) age was 61.9 ± 12.3 years (age range, 22-80 years), 35 patients (57%) were male, and 26 (43%) were female. 
Intuitiveness Group: Injection Time without Instruction
Mean injection time was significantly shorter with FlexPen than with OptiClik (excluding cartridge insertion) among patients in the intuitiveness group (2 min and 25 s versus 2 min and 50 s, p = .008) ( Table 2) . When cartridge insertion was included, the difference in the mean injection time was 2 min and 15 s longer with OptiClik (p < .0001) when compared with FlexPen. The mean total time for performing the injection with OptiClik was 4 min and 40 s.
Additional Intuitiveness Endpoints
Sixty-nine percent (n = 22) of patients chose FlexPen as the most intuitive insulin pen, while 22% (n = 7) chose OptiClik (p = .001) ( Table 3) . Few patients were confident in using either pen without instructions (FlexPen, 31%, n = 10; OptiClik, 16%, n = 5; nonsignificant).
Instruction Time Group: Injection Time with Instruction
Mean instruction and injection time was significantly shorter with FlexPen than with OptiClik among patients in the instruction time group (2 min and 28 s versus 3 min and 59 s, p < .001) ( Table 2) . When cartridge insertion was included, the difference in the mean total instruction and injection time was 2 min and 44 s longer for OptiClik (p < .001). The mean total instruction time for OptiClik was 5 min and 12 s.
Secondary Endpoints: Questionnaire Responses
Learning to Use Questionnaire No patients in the instruction time group found FlexPen difficult to learn (0%), wheras 45% of patients found OptiClik difficult or very difficult to learn ( Table 4) .
In both groups, FlexPen was considered the easiest pen to learn how to use compared with OptiClik (82% versus 7%, p < .001).
Handling and Acceptance Questionnaire
More patients trusted FlexPen to deliver injections (39% versus 15%, p = .006) and to be the safest insulin pen to operate (36% versus 15%, p = .014) compared with OptiClik (Table 5 ). More patients also trusted the accuracy of FlexPen over OptiClik in terms of confidence in each pen to inject a full dose (61% versus 12%, p < .001).
Overall more patients preferred FlexPen over OptiClik (82% versus 13%, p < .001).
The reusable OptiClik was rated the highest "quality" pen compared with FlexPen (48% versus 26%, p = .045), yet significantly more patients considered it easier to inject with FlexPen (67% versus 13%, p < .001) and easier to know if the injection push button was completely depressed compared with OptiClik (p < .001). In addition, significantly more patients rated FlexPen simpler to use overall (82% versus 12%, p < .001) and more convenient to use than OptiClik (71% versus 12%, p < .001).
Important Device Features Questionnaire
Patients rated confidence in injecting the correct dose as the most important feature of each insulin pen (Table 6) . Likewise, confidence in setting the correct dose was "extremely important" for 44% and "pretty important" for 51% of patients. Appropriateness of the appearance of the pen was considered the least important feature. 
Discussion
In this study, mean injection time was significantly shorter with the FlexPen than with the OptiClik pen, with or without instruction. This difference was greater when cartridge insertion was included for OptiClik. OptiClik was rated as having the highest quality compared with FlexPen, which could possibly be due to OptiClik being a reusable device wheras FlexPen is disposable. As expected for a device designed to be reused for years, the OptiClik was rated higher on quality than the prefilled FlexPen. In this study, patients' rating of quality was based on subjective perception. As such, it may be speculated that "quality" refers to the durability of the device, which would be in line with OptiClik being reusable and the FlexPen being disposable. However, FlexPen was rated highest with regard to trust and accuracy, where significantly more patients were confident that FlexPen would inject the full dose and be the safest insulin pen to operate as compared with OptiClik. In general, among all patients, injecting the correct amount of insulin was rated the most important device feature. In addition, FlexPen earned significantly higher ratings than OptiClik on the operating quality of several mechanical features of the insulin pens. For example, significantly more patients rated FlexPen easiest to inject and simplest to use. Significantly more patients also considered it easier to know if the injection push button was completely depressed with FlexPen compared with OptiClik.
The results of this investigation are consistent with previous studies examining FlexPen versus other insulin pens or the conventional vial and syringe. 19, 22, [24] [25] [26] [27] For example, Dreyer 25 observed a significantly higher preference for FlexPen compared with the NovoLet ® pen (Novo Nordisk A/S, Copenhagen, Denmark) (p < .0001) regarding confidence in delivering correct dose (63% versus 9%), ease of dose setting (71% versus 8%), discreetness in public (39% versus 9%), handling (54% versus 12%), and ease of use (73% versus 8%), as well as overall preference for continuing use (77% versus 12%).
In the current study, FlexPen was rated the most intuitive pen by the intuitiveness group. Similarly, in a randomized crossover study of 61 patients with type 2 diabetes, the NovoMix ® 30 (biphasic insulin aspart) FlexPen (Novo Nordisk A/S, Copenhagen, Denmark) was found to be significantly more intuitive (p < .05), simpler to use (p < .01), and easier to learn (p < .01) than the HumaPen ® Luxura™ with insulin lispro (Eli Lilly and Company, Indianapolis, IN) . 26 Mean total instruction time (including cartridge insertion for HumaPen Luxura) was also significantly shorter for the FlexPen (43 s versus 1 min and 7 s, p = .0004). 26 Another randomized crossover study comparing the NovoMix 30 FlexPen with the Humalog ® Mix25™ (insulin lispro mix) pen found a significantly higher preference for FlexPen (74.6% versus 14.3%, p < .001) among the 133 participants with type 2 diabetes. 27 In addition, patients expressed greater confidence in FlexPen versus the Humalog pen in setting (36% versus 8.5%, p < .001) and injecting the correct dose every time (40% versus 9%, p < .001), managing daily injections (48% versus 7%, p < .001), and controlling blood sugar level (35% versus 15%, p < .005). 27
Insulin pens that are simple to learn to use are more likely to give patients the confidence to self-inject and therefore lead to better adherence and improved glycemic control, leading to decreased health care costs. 16 Consequently it is reassuring to observe in our study that patients found FlexPen easy to learn.
Preference for FlexPen is also evident in studies involving the conventional vial and syringe. 19, 22 For example, 74% of 108 patients with type 1 or 2 diabetes preferred to continue using FlexPen versus 20% who preferred to continue with the vial and syringe in a crossover study by Korytkowski and colleagues. 19 The majority of patients found FlexPen easier overall to use (74% versus 21%), more discreet to use in public than the vial and syringe (85% versus 9%), and were more confident in using FlexPen in general (82% versus 11%). Patients were more confident in using FlexPen compared with the vial and syringe to deliver an accurate dose (73% versus 19%) and the required dose (82% versus 11%) and also to self-maintain glycemic control (61% versus 16%). 19 This statistically significant improvement in glycemic control attests to patient confidence in FlexPen to deliver accurate doses.
Although the current investigation did not measure the accuracy of dose delivery, it did record patients' confidence in each pen to deliver full doses. Ultimately more patients trusted FlexPen to deliver doses accurately. Several studies corroborate this patient confidence in FlexPen by demonstrating its greater dosing accuracy compared with other insulin pens. 23, 24, 28, 29 In a study comparing FlexPen with OptiClik, FlexPen delivered doses that were significantly more accurate at 10 U (p < .0001) and 30 U (p < .0001), and all FlexPen doses were delivered within the specified range. 29 OptiClik, on the other hand, underdosed for 17.1% of doses at 10 U and for 28.9% of doses at 30 U. These findings were corroborated in a study by Nayak and Clement, 28 where, for a 10 U dose, 99.47% of doses delivered by FlexPen were accurate compared with 90.53% of doses delivered by OptiClik. For a 30 U dose, 100% versus 87.5% of doses delivered by FlexPen and OptiClik, respectively, were accurate. 28 In another study, FlexPen proved to be more accurate in injecting 5, 10, and 30 U doses than SoloSTAR ® (Sanofi-Aventis, Paris, France), with all FlexPen doses within the specified limits for 5 and 30 U doses and 1.3% of doses outside the specified limits for the 10 U dose. 23 In contrast, SoloSTAR dosed outside the specified limits for all three doses, underdosing 1.6%, 29.3%, and 33.3% of the 5, 10, and 30 U doses, respectively. Similarly, in a head-to-head comparison of four insulin pens (FlexPen, OptiClik, SoloSTAR, and HumaPen Luxura), FlexPen exhibited significantly superior dosing accuracy versus OptiClik and SoloSTAR. 24
Insulin pens in general offer a convenient, accurate, preferred alternative to the vial and syringe, improving quality of life among patients. 8, [19] [20] [21] [22] As many studies depict, patients are more compliant with their treatment when using insulin pens rather than vial and syringe. 16, [18] [19] [20] [21] Those pens that instill patient confidence based on ease of learning and superior handling may improve compliance to intensive insulin therapy.
Conclusions
In this investigation the FlexPen was found to be faster to teach, simpler to use, and more trusted by patients compared with the OptiClik pen. Mean injection time was significantly shorter for the FlexPen than for OptiClik, with or without instruction. These results have been corroborated in several other studies comparing FlexPen with other insulin pens or the conventional vial and syringe. This study highlights not only how easy it is for patients to both use and learn to use the FlexPen, but also the ease with which health care providers can teach patients to use it. These findings also demonstrate the importance of instructing patients on the correct use of insulin injection devices so patients feel confident in performing injections and, ultimately, in their ability to self-manage their diabetes.
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